In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Broad Institute · Harvard University · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,139
total citations
- FWCI
- 45.40
- Percentile
- 100%
- References
- 36
Citations per year
Authors
19- RTRobert T. MangusoCorresponding
Broad Institute, Harvard University, Dana-Farber Cancer Institute, Massachusetts Institute of Technology
- HWHans W. Pope
Broad Institute, Dana-Farber Cancer Institute, Massachusetts Institute of Technology
- MDMargaret D. Zimmer
Broad Institute, Massachusetts Institute of Technology, Dana-Farber Cancer Institute
- FDFlavian D. Brown
Harvard University, Dana-Farber Cancer Institute
- KBKathleen B. Yates
Massachusetts Institute of Technology, Dana-Farber Cancer Institute, Broad Institute
Topics & keywords
Topics
Keywords
- Immunotherapy
- Cancer immunotherapy
- Immune checkpoint
- Cancer research
- Biology
- CRISPR
- Cancer
- Immune system
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.